RecruitingPhase 1Phase 2NCT05372354

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Sponsor

Bristol-Myers Squibb

Enrollment

260 participants

Start Date

Oct 18, 2022

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing CC-92480 (also called BMS-986348), a new drug for multiple myeloma (a blood cancer of plasma cells), in combination with other cancer treatments. It is being studied in patients whose myeloma has returned or stopped responding to multiple prior therapies. **You may be eligible if...** - You have multiple myeloma that has relapsed (come back) or is refractory (no longer responding to treatment) - Your disease has progressed during or after your most recent therapy - You are in good performance status (ECOG 0 or 1) - You agree to follow the pregnancy prevention plan required by the drug **You may NOT be eligible if...** - Your myeloma has spread to the brain or spinal fluid - You have plasma cell leukemia, POEMS syndrome, or significant amyloidosis - You have significant heart disease - You have had a recent COVID-19 infection (within 14–28 days) - You have had an allogeneic (donor) stem cell transplant - You have had an autologous (own cells) transplant within the past 12 weeks - You have received any anti-myeloma treatment within the past 14 days Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.